共 587 条
[1]
Duffy MJ(1994)Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer Cancer 74 2276-2280
[2]
Reilly D(1995)Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer Int.J.Cancer 61 597-600
[3]
McDermott E(1995)Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer Clinical Cancer Research 1 1079-1087
[4]
O'Higgins N(2008)uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial Advances in Clinical Chemistry 45 31-45
[5]
Fennelly JJ(2001)Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 Journal of the National Cancer Institute 93 913-920
[6]
Andreasen PA(2008)The plasminogen activator inhibitor “paradox” in cancer Immunology Letters 118 116-124
[7]
Duggan C(2011)Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 Expert Review of Molecular Diagnostics 11 617-634
[8]
Maguire T(2013)The apparent uPA/PAI-1 paradox in cancer: more than meets the eye Seminars in Thrombosis and Hemostasis 39 382-391
[9]
McDermott E(1994)Plasminogen activator inhibitor-1 and prognosis in primary breast cancer J.Clin.Oncol. 12 1648-1658
[10]
OHiggins N(1995)Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer J.Natl.Cancer Inst. 87 751-756